Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab

Firm Prepares To Launch First Humira Biosimilar At A ‘Pivotal Time’ For The US Market

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.